|
The Indian Pharmacist Association, a Delhi-based pharmacists body, has moved the Union ministry of health and family welfare seeking an immediate withdrawal or amendment of the recently notified Recruitment Rules, 2026, for the post of Drugs Controller General of India (DCGI).
In a strongly worded representation addressed to Union health minister JP Nadda, the association expressed serious concern over the new eligibility criteria, which they claim could undermine the integrity of the country’s drug regulatory framework. The controversy stems from the notification vide G.S.R. 296(E) dated April 20, 2026, which introduces a significant shift in the essential qualifications for the apex regulatory position. The new rules have opened the doors for candidates from a wide range of non-pharmacy backgrounds, including various engineering disciplines such as biomedical, mechanical, and electrical, as well as general life sciences. The Indian Pharmacist Association contends that allowing individuals without a core pharmaceutical background to lead the Central Drugs Standard Control Organisation (CDSCO) is a retrograde step.
Key objections raised by the association include the potential dilution of core pharmaceutical regulatory expertise and a direct contradiction with the spirit of the Drugs and Cosmetics Act, 1940. The representation highlights that the interpretation and enforcement of drug laws require domain-specific knowledge in pharmaceutics and pharmacology. The secretary general of the Indian Pharmacist Association, Bhupendra Kumar, emphasized that these specialized functions cannot be substituted by general engineering or science backgrounds without risking regulatory oversight.
Kumar further argued that the amendment marginalizes thousands of highly qualified pharmacy professionals in India, including those holding Pharm.D and M.Pharm degrees. By sidelining these specialists, he says the government is ignoring a talent pool specifically trained in drug regulation, clinical research, and pharmacovigilance. This move, he argues, sends a discouraging signal to the professional pharmacy community that has been instrumental in maintaining the ‘pharmacy of the world’ status. Public health risks remain at the forefront of the association’s grievances, with the letter warning of sub-optimal decision-making in critical areas like drug approvals and clinical trial oversight.
The pharmacists association pointed out that globally recognized regulatory authorities, such as the US FDA and the European Medicines Agency, rely heavily on professionals with strong pharmaceutical and medical backgrounds. They pointed out that the current amendment moves India away from these established global best practices. The demands placed before the health minister include a restriction of the eligibility for the post of DCGI to candidates with core qualifications in Pharmacy, Pharmaceutical Sciences, or Clinical Pharmacology. Besides, the professional body has called for the formation of an expert committee to review the qualification criteria.
The representation concludes with a plea for the health minister's kind intervention to rectify the policy decision in the larger interest of patient safety and professional integrity. The association maintains that the position of the national drugs controller is too critical to be opened to unrelated disciplines. As the industry awaits a response from the ministry, the pharma professional community remains on high alert regarding the future of regulatory leadership in the country.
|